An Open Trial of Reboxetine in HIV-Seropositive Outpatients With Major Depressive Disorder
J Clin Psychiatry 2003;64:421-424
© Copyright 2014 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Background: The prevalence of major depressive
disorder (MDD) in human immunodeficiency virus (HIV)-seropositive
patients is higher than in the general population. The treatment
of comorbidities of HIV infection, such as depression, is an
important target in the clinical management of these patients.
The use of antidepressants in HIV patients can be complicated by
the pharmacokinetic interaction between antidepressants and
antiretroviral agents. Several antidepressants and
antiretrovirals are metabolized by cytochrome P450 (CYP450).
Reboxetine is a noradrenergic antidepressant that is not
metabolized by CYP450 and may offer a valuable option in the
treatment of MDD in HIV-seropositive patients.
Method: Twenty HIV-infected outpatients with MDD
according to DSM-IV criteria were treated with reboxetine, 8
mg/day, for 12 weeks within an open trial design. Outcome
measures included the Montgomery-Asberg Depression Rating Scale
(MADRS) and a side effect profile. Data were gathered from July
2000 to March 2001.
Results: Seventy-five percent of patients
(N = 15) completed the trial. All patients who completed the
trial had an improvement equal to or higher than a 50% reduction
in their MADRS scores at endpoint. The most frequent adverse
effects were insomnia, sweating, and shivering.
Conclusion: Within this open trial,
reboxetine was found to be effective in reducing depressive
symptoms in HIV illness. The rate of dropout (25%) suggests that
reboxetine may be well tolerated in this population.